CD137 (ILA/4-1BB), a member of the TNF receptor family, induces monocyte activation via bidirectional signaling

被引:0
|
作者
Langstein, J
Michel, J
Fritsche, J
Kreutz, M
Andreesen, R
Schwarz, H [1 ]
机构
[1] Univ Regensburg, Dept Pathol, D-93042 Regensburg, Germany
[2] Univ Regensburg, Dept Hematol, D-93042 Regensburg, Germany
来源
JOURNAL OF IMMUNOLOGY | 1998年 / 160卷 / 05期
关键词
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD137 (ILA/4-1BB), a member of the TNF receptor family, was shown previously to inhibit proliferation and to induce apoptosis in T lymphocytes. In this study, we identify CD137 as a novel and potent monocyte activation factor, CD137 protein induces expression of IL-6, IL-8, and TNF-alpha, and inhibits expression of IL-10. Furthermore, CD137 differentially regulates expression of cell surface receptors, It induces expression of ICAM and reduces expression of Fc gamma RIII, while levels: of HLA-DR remain unchanged. CD137 also promotes adherence of monocytes. These effects of CD137 require immobilization of CD137 protein, indicating that they are mediated by cross-linking of a corresponding ligand/coreceptor expressed on monocytes.
引用
收藏
页码:2488 / 2494
页数:7
相关论文
共 50 条
  • [31] Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
    Sanchez-Paulete, Alfonso R.
    Labiano, Sara
    Rodriguez-Ruiz, Maria E.
    Azpilikueta, Arantza
    Etxeberria, Inaki
    Bolanos, Elixabet
    Lang, Valerie
    Rodriguez, Manuel
    Angela Aznar, M.
    Jure-Kunkel, Maria
    Melero, Ignacio
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 (03) : 513 - 522
  • [32] Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis
    Hamaguchi, Yasuhito
    Hasegawa, Minoru
    Matsushita, Takashi
    Komura, Kazuhiro
    Takehara, Kazuhiko
    Fujimoto, Manabu
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2009, 53 (02) : 159 - 161
  • [33] Targeting CD137 (4-1BB) towards improved safety and efficacy for cancer immunotherapy
    Liu, Guizhong
    Luo, Peter
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [34] Contribution of 4-1BB (CD137) costimulatory molecule to skin allograft rejection.
    Wolisi, G
    Srirangam, A
    Vinay, D
    Kwon, BS
    FASEB JOURNAL, 1999, 13 (05): : A661 - A661
  • [35] The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
    Claus, Christina
    Ferrara-Koller, Claudia
    Klein, Christian
    MABS, 2023, 15 (01)
  • [36] Expression of 4-1BB(CD137) and its ligand 4-1BBL in human atherosclerosis
    Ghaderi, M
    Wågsäter, D
    Olofsson, P
    Sheikine, Y
    Sirsjö, A
    ATHEROSCLEROSIS SUPPLEMENTS, 2004, 5 (01) : 6 - 6
  • [37] Assessing CD137 (4-1BB) As a Therapeutic Target in B-Cell Neoplasms
    Cohen, Adam D.
    Joshi, Indira D.
    Robu, Valentin
    Borghaei, Hossein
    Al-Saleem, Tahseen I.
    Jure-Kunkel, Maria
    Smith, Mitchell R.
    BLOOD, 2011, 118 (21) : 1594 - 1595
  • [38] Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
    Melero, Ignacio
    Murillo, Oihana
    Dubrot, Juan
    Hervas-Stubbs, Sandra
    Perez-Gracia, Jose L.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (08) : 383 - 390
  • [39] Functional expression of 4-1BB (CD137) in the inflammatory tissue in Crohn's disease
    Maerten, P
    Geboes, K
    De Hertogh, G
    Shen, C
    Cadot, P
    Bullens, DMA
    Van Assche, G
    Penninckx, F
    Rutgeerts, P
    Ceuppens, JL
    CLINICAL IMMUNOLOGY, 2004, 112 (03) : 239 - 246
  • [40] Role of CD137 (4-1BB) in the SCID T cell transfer colitis model
    Maerten, P
    Shen, C
    Cadot, P
    Van Assche, G
    Geboes, K
    Kwon, B
    Rutgeerts, P
    Ceuppens, J
    GASTROENTEROLOGY, 2003, 124 (04) : A333 - A333